News
FTH
18.69
-0.32%
-0.06
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 2d ago
Sensei Biotherapeutics, Inc. Appoints Adam Schayowitz to Board of Directors on October 23, 2026
NASDAQ · 5d ago
Guggenheim Sticks to Their Buy Rating for Faeth Therapeutics (FTH)
TipRanks · 5d ago
Faeth Therapeutics Adds Oncology Expert to Board
TipRanks · 5d ago
*Faeth Appoints Adam Schayowitz to Bd of Directors
Dow Jones · 5d ago
Faeth Therapeutics Price Target Maintained With a $55.00/Share by BTIG
Dow Jones · 5d ago
BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target
Benzinga · 5d ago
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Barchart · 5d ago
BTIG Reaffirms Their Buy Rating on Faeth Therapeutics (FTH)
TipRanks · 5d ago
Weekly Report: what happened at FTH last week (1019-1023)?
Weekly Report · 6d ago
Faeth Therapeutics presents updated preclinical data on PIKTOR at ESMO
TipRanks · 10/23 13:20
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
Barchart · 10/23 08:15
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Faeth Therapeutics (FTH)
TipRanks · 10/22 18:40
Weekly Report: what happened at FTH last week (1012-1016)?
Weekly Report · 10/19 09:06
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Barchart · 10/19 06:30
William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating
Benzinga · 10/16 14:31
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Faeth Therapeutics (FTH)
TipRanks · 10/16 09:40
Faeth Therapeutics initiated with an Outperform at William Blair
TipRanks · 10/16 01:10
Faeth Therapeutics initiated with an Outperform at LifeSci Capital
TipRanks · 10/15 13:35
Weekly Report: what happened at FTH last week (1005-1009)?
Weekly Report · 10/12 09:06
More
Webull provides a variety of real-time FTH stock news. You can receive the latest news about Faeth Therapeutics, Inc through multiple platforms. This information may help you make smarter investment decisions.
About FTH
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.